Lilly (Eli)

Jefferies Remains a Buy on Eli Lilly and Company (LLY)

Eli Lilly and Company (NYSE:LLY) is one of the Good Stocks to Buy Now. On March 20, Jefferies reiterated a Buy rating on Eli Lilly and Company (NYSE:LLY) with a price target of $1,300. ​The rating is based on the company’s prescription data for GLP-1 medications. Oral Wegovy had roughly 89,300 IMS p

Is Eli Lilly (LLY) The Best Healthcare Stock to Buy According to Jim Cramer?

We just covered the Jim Cramer Stock Portfolio: Top 10 Stock Picks. Eli Lilly and Company (NYSE:LLY) ranks #9 (see the Jim Cramer’s top 5 stock picks in 2026 here). Jim Cramer has long been a believer in Eli Lilly and Company (NYSE:LLY). In November, he said on CNBC that the company is likely to hit

Eli Lilly (LLY) Gained From Growth in its GLP-1 Franchises Drugs

RiverPark Advisors, an investment advisory firm and sponsor of the RiverPark family of mutual funds, released its “RiverPark Large Growth Fund” Q4 2025 investor letter. A copy of the letter can be downloaded here. The US stock market delivered modest gains in the quarter with the S&P 500 index (“S&P

Eli Lilly and Company (LLY) Expands Zepbound Access as Pricing Reforms Boost Long-Term Growth Outlook

Eli Lilly and Company (NYSE:LLY) is one of the best forever stocks to buy now. On March 16, Eli Lilly and Company (NYSE:LLY) announced that its weight-loss drug Zepbound will be available for self-pay starting at $299 per month for the 2.5 mg dose through LillyDirect and major pharmacies, expanding